Glucotrack Receives Nasdaq Delisting Notice; Trading to Suspend October 30
Glucotrack, Inc. received written notice from the Nasdaq Hearings Panel that its securities will be delisted because the company's closing bid price was $0.87 on October 14, 2026, failing to satisfy the terms of a compliance exception that required maintaining a closing bid price of at least $1.00 for each trading day through November 9, 2026. Trading in the company's common stock on Nasdaq will be suspended at the open of trading on October 30, 2026. The company expects its shares to be quoted by OTC Markets Gr...
Key takeaways
Nasdaq Hearings Panel determined to delist Glucotrack after the company's closing bid price fell to $0.87 on October 14, 2026, below the $1.00 minimum required under a previously granted compliance exception.
Trading in Glucotrack common stock on Nasdaq will be suspended at the open of trading on October 30, 2026.
The company expects Nasdaq to file a Form 25 with the SEC to delist and deregister the company's securities under Section 12(b) of the Securities Exchange Act of 1934.
Glucotrack plans to have its shares quoted by OTC Markets Group on the OTCID Market following the Nasdaq suspension.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow GCTK in real time
Get material earnings, filing, IR, and earnings-call alerts by email.